About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Alcon Research Ltd. v. Akorn Inc.
1:15-cv-00474; filed June 11, 2015 in the District Court of Delaware

Infringement of U.S. Patent Nos. 8,268,299 ("Self Preserved Aqueous Pharmaceutical Compositions," issued September 18, 2012), 8,323,630 (same title, issued December 4, 2012), and 8,388,941 (same title, issued March 5, 2013) following a Paragraph IV certification as part of Akorn's filing of an ANDA to manufacture a generic version of Alcon's Travatan Z® (travoprost ophthalmic solution, used to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertention).  View the complaint here.

Novartis Pharmaceuticals Corp. et al. v. Roxane Laboratories Inc.
1:15-cv-00474; filed June 10, 2015 in the District Court of Delaware

• Plaintiffs:  Novartis Pharmaceuticals Corp.; Novartis AG
• Defendant:  Roxane Laboratories Inc.

Infringement of U.S. Patent Nos. 9,006,224 ("Neuroendocrine Tumor Treatment," issued April 14, 2015) and 8,410,131 ("Cancer Treatment," issued April 2, 2013) following a Paragraph IV certification as part of Roxane's filing of an ANDA to manufacture a generic version of Novartis' Afinitor® (everolimus, used for the treatment of: postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole; adults with progressive neuroendocrine tumors of pancreatic origin that are unresectable, locally advanced or metastatic; adults with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib; adults with renal angiomyolipoma and tuberous sclerosis complex, not requiring immediate surgery; and pediatric and adult patients with tuberous sclerosis complex who have subependymal giant cell astrocytoma that requires therapeutic intervention but cannot be curatively resected).  View the complaint here.

Novartis Pharmaceuticals Corp. et al. v. Par Pharmaceutical, Inc.
1:15-cv-00475; filed June 10, 2015 in the District Court of Delaware

• Plaintiffs:  Novartis Pharmaceuticals Corp.; Novartis AG
• Defendant:  Par Pharmaceutical, Inc.

Infringement of U.S. Patent No. 9,006,224 ("Neuroendocrine Tumor Treatment," issued April 14, 2015) following a Paragraph IV certification as part of Par's filing of an ANDA to manufacture a generic version of Novartis' Afinitor® (everolimus, used for the treatment of: postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole; adults with progressive neuroendocrine tumors of pancreatic origin that are unresectable, locally advanced or metastatic; adults with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib; adults with renal angiomyolipoma and tuberous sclerosis complex, not requiring immediate surgery; and pediatric and adult patients with tuberous sclerosis complex who have subependymal giant cell astrocytoma that requires therapeutic intervention but cannot be curatively resected).  View the complaint here.

Reckitt Benckiser Pharmaceuticals Inc. et al. v. Alvogen Pine Brook Inc.
1:15-cv-00477; filed June 10, 2015 in the District Court of Delaware

• Plaintiffs:  Reckitt Benckiser Pharmaceuticals Inc.; RB Pharmaceuticals Ltd.; MonoSol Rx LLC
• Defendant:  Alvogen Pine Brook Inc.

Infringement of U.S. Patent Nos. 8,475,832 ("Sublingual and Buccal Film Compositions," issued July 2, 2013), 8,017,150 ("Polyethylene Oxide-Based Films and Drug Delivery Systems Made Therefrom," issued on September 13, 2011), 8,603,514 ("Uniform Films for Rapid Dissolve Dosage Form Incorporating Taste-Masking Compositions," issued December 10, 2013), 8,900,497 ("Process for Making a Film Having a Substantially Uniform Distribution of Components," issued December 2, 2014) and 8,906,277 ("Process for Manufacturing a Resulting Pharmaceutical Film," issued December 9, 2014) following a Paragraph IV certification as part of Alvogen's filing of an ANDA to manufacture a generic version of Reckitt Benckiser's Suboxone® (buprenorphine hydrochloride and naloxone hydrochloride sublingual film, used for the maintenance treatment of opioid dependence).  View the complaint here.